Asia-Pacific Cell and Gene Therapy Biomanufacturing Market - Analysis and Forecast, 2022-2031

Report
108 Pages
November 2023
Region: Asia Pacific
BIS Research
ID: 5907718

The Asia Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market is expected to grow at a CAGR of 17.88% from $1.96 Billion in 2022 to $8.60 Billion in 2031 in the forecasted period of 2022-2031. APAC cell and gene therapy biomanufacturing industry is expected to grow due in part to the increasing number of authorized treatments and growing infrastructural requirements. Extensive biomanufacturing capabilities are also required due to the expanding target indications for gene and cell treatments.

Market Introduction

The industry for cell and gene therapy biomanufacturing in Asia-Pacific (APAC) is about to undergo a period of rapid expansion and change. This area is set to become a center for state-of-the-art biomanufacturing due to the rise of authorized medicines and the rising requirements for infrastructure. A significant need for large-scale biomanufacturing facilities in Asia-Pacific is being driven by the broadening range of target indications for gene and cell therapies. The APAC market for cell and gene therapy biomanufacturing is growing as a result of continued investment in this area by governments, pharmaceutical corporations, and academic organizations, which is helping to develop novel and perhaps life-saving medical therapies. In addition to seeing the creation of cutting-edge treatments, this area is essential to the world's biomanufacturing industry.

Market Segmentation:

Segmentation 1: by Product Type

Consumables
Equipment
Software Solutions

Segmentation 2: by End User

Life Science Companies
Contract Research Organizations (CROs)
Contract Manufacturing Organizations (CMOs)
Cell Banks

Segmentation 3: by Country

China
Japan
India
South Korea
Australia/New Zealand
Rest-of-Asia-Pacific

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific Cell and Gene Therapy Biomanufacturing Market:

Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
Robust Clinical Pipeline Creating a Demand for Biomanufacturing Infrastructure

The market is expected to face some limitations as well due to the following challenges:

High Set-Up Cost of Biomanufacturing Facilities

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy biomanufacturing market (by product type) has been segmented into consumables, equipment, and software solutions.

Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for upstream processing, harvesting, downstream processing, and other applications. Various companies are providing consumables and equipment aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current cell and gene therapy biomanufacturing market.

Competitive Strategy: Key players in the APAC cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

WuXi AppTec

This product will be delivered within 3-5 business days.

1 Markets

1.1 Industry Outlook
1.1.1 Market Overview and Ecosystem
1.1.2 Key Trends
1.1.2.1 Biomanufacturing 4.0
1.1.2.2 Growing Single-Use Technology Market Penetration
1.1.2.3 Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
1.1.2.4 Leveraging Various Key Strategies to Diversify the Product Portfolio
1.1.3 Opportunity Assessment
1.1.4 Regulatory Framework
1.1.5 Product Benchmarking
1.1.5.1 Product Benchmarking (by Product Type)
1.1.5.2 Comparative Analysis (by Equipment)
1.1.6 Patent Analysis
1.1.6.1 Patent Analysis (by Year)
1.1.6.2 Patent Analysis (by Country)
1.1.6.3 Awaited Technologies
1.1.7 Business Model Analysis
1.1.8 Pipeline Products
1.1.9 Technology Adoption Matrix
1.1.10 Funding Scenario
1.1.11 Key Success Factors
1.2 Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
1.2.1 Recommendations to Manufacturers
1.3 Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market

2 Asia-Pacific

2.1 Asia-Pacific
2.1.1 Key Findings and Opportunity Assessment
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Sizing and Forecast Analysis
2.1.3.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
2.1.3.3.1 China
2.1.3.3.1.1 China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.1.2 China Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.2 Japan
2.1.3.3.2.1 Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.2.2 Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.3 India
2.1.3.3.3.1 India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.3.2 India Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.4 South Korea
2.1.3.3.4.1 South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.4.2 South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.5 Australia/New Zealand
2.1.3.3.5.1 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.5.2 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
2.1.3.3.6 Rest-of-Asia-Pacific
2.1.3.3.6.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
2.1.3.3.6.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)

3 Markets - Competitive Benchmarking and Company Profiles

3.1 Competitive Benchmarking
3.1.1 Competitive Landscape
3.1.1.1 Segmental Growth Share Matrix
3.1.1.1.1 Growth Share Analysis (by Product Type)
3.1.1.1.2 Growth Share Analysis (by Application)
3.1.1.2 Competitive Index (Unmet Needs and Innovations)
3.1.1.3 Company Position Analysis
3.1.1.4 Key Strategies and Developments
3.1.1.4.1 Funding Activities
3.1.1.4.2 New Offerings
3.1.1.4.3 Mergers and Acquisitions
3.1.1.4.4 Partnerships, Alliances, and Business Expansions
3.1.1.4.5 Key Development Analysis
3.2 Company Share Analysis
3.3 Company Profiles
3.3.1 WuXi AppTec
3.3.1.1 Company Overview
3.3.1.2 Role of WuXi AppTec in the Cell and Gene Therapy Biomanufacturing Market
3.3.1.3 Major Product: Key Specifications
3.3.1.4 Customers and Competitions/Opportunities
3.3.1.4.1 Key Competitors
3.3.1.5 Analyst Perspective

List of Figures

Figure 1: Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 2: Cell and Gene Therapy Biomanufacturing Market: Drivers, Restraints, and Opportunities
Figure 3: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Impact Analysis
Figure 4: Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 5: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Region), $Billion, 2021 and 2031
Figure 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Share of Key Developments and Strategies (by Category), January 2020-January 2023
Figure 7: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Segmentation
Figure 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market: Research Methodology
Figure 9: Primary Research Methodology
Figure 10: Bottom-Up Approach (Segment-Wise Analysis)
Figure 11: Top-Down Approach (Segment-Wise Analysis)
Figure 12: Market Overview and Ecosystem
Figure 13: Insights on Strategies Adopted by Major Players, January 2020-January 2023
Figure 14: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Trends, Market Shift, 2022-2031
Figure 15: TcBuster vs. Viral Gene Engineering Technology, Comparative Analysis
Figure 16: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Year), January 2020-December 2022
Figure 17: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Patent Analysis (by Country), January 2020-December 2022
Figure 18: Anticipated Regulatory Milestones in 2023
Figure 19: Anticipated Regulatory Approval, U.S. and EU, 2023
Figure 20: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Technology Adoption Matrix
Figure 21: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Success Factors
Figure 22: Impact of COVID-19 on CGT Developmental Activities
Figure 23: Progress in Cell and Gene Therapy (CGT) Regulation during COVID-19
Figure 24: Ways to Increase Supply Chain and Manufacturing
Figure 25: Impact on Biopharmaceutical Industries
Figure 26: Cell and Gene Therapy Biomanufacturing Market Share (by Region)
Figure 27: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Incremental Revenue Opportunity (by Country), $Billion, 2021-2031
Figure 28: Ongoing Clinical Trials, Asia-Pacific (by Country)
Figure 29: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
Figure 30: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 31: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion, 2021-2031
Figure 32: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion, 2021-2031
Figure 33: China Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 34: China Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 35: China Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 36: Japan Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 37: Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 38: Japan Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 39: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, India, 2020 vs. 2040
Figure 40: India Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 41: India Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 42: India Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 43: Incidence of Leukemia, Multiple Myeloma and Immunoproliferative Diseases, and Non-Hodgkin’s Lymphoma, South Korea, 2020 vs. 2040
Figure 44: South Korea Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 45: South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 46: South Korea Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 47: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 48: New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 49: Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 50: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, $Billion, 2021-2031
Figure 51: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), $Billion 2021-2031
Figure 52: Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User), $Billion 2021-2031
Figure 53: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), 2021-2031
Figure 54: Growth Share Analysis for Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Application), 2021-2031
Figure 55: Competitive Index, Unmet Needs, Solutions, and Impacts
Figure 56: Company Position Analysis
Figure 57: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Total Number of Key Developments, January 2020-January 2023
Figure 58: Funding Activities, January 2020-January 2023
Figure 59: New Offerings, January 2020-September 2023
Figure 60: Mergers and Acquisitions, January 2020-January 2023
Figure 61: Partnerships, Alliances, and Business Expansion Activities, January 2020-January 2023
Figure 62: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Company Share Analysis, % Share, 2021
Figure 63: WuXi AppTec: Product Portfolio

List of Tables

Table 1: Key Questions Answered in the Report
Table 2: Single-Use and Stainless-Steel Facilities, Comparative Analysis
Table 3: Asia-Pacific Regulatory Scenario: Cell and Gene Therapy Biomanufacturing Market
Table 4: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type), Product Benchmarking
Table 5: Comparative Analysis of Various Bioreactors Offered by Key Players
Table 6: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Awaited Technologies
Table 7: Business Models, Key Features
Table 8: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Dynamics, Impact Analysis
Table 9: Approved Cell and Gene Therapies, Japan
Table 10: Ongoing Industry Sponsored Cell and Gene Therapy Clinical Trials
Table 11: Asia-Pacific Cell and Gene Therapy Biomanufacturing Market, Key Development Analysis, January 2020-January 2023

Executive Summary

The Asia-Pacific cell and gene therapy biomanufacturing market is estimated to reach $8.60 billion by 2031, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 17.88% during the forecast period 2022-2031.

The Asia-Pacific region is the fastest-growing region for the global cell and gene therapy biomanufacturing market due to the robust clinical pipeline, rising number of cell and gene therapy developers, and growing incidence of target indication groups.

The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market: Drivers and Challenges

In conjunction with the ongoing efforts in the U.S. and Europe, cell and gene therapy research has become an increasingly active and global initiative in Asia-Pacific. With a large geographic area and substantial ethnic and cultural diversity, the region has become a focus area for a growing number of cell and gene therapies.

Another factor that is driving the cell and gene therapy market is the rising incidence of hematologic malignancies in the region.

However, the high cost of setting up the biomanufacturing facilities is expected to hinder the growth of the Asia-Pacific cell and gene therapy biomanufacturing market.

USPs of report

The major USP of the report is the inclusion of software solutions along with the consumables and equipment required for the manufacturing of cell and gene therapy.
The report provides numerical projections for the product type as well as end user
The report also comprises key regulations, competitive landscape, key drivers and restraints, patent analysis, business model analysis, and company profiles with a detailed analysis of the strategies undertaken by the major company to strengthen its market presence.

Analyst’s Perspective on Asia-Pacific Cell and Gene Therapy Biomanufacturing Market

The Principal Analyst states, 'The cell and gene therapy biomanufacturing market is strongly driven by the rising incidence of target diseases such as orphan diseases, cancers, metabolic disorders, and autoimmune disorders, among others, as well as the increasing approval of cell and gene therapies. The cell and gene therapy biomanufacturing market has witnessed a steady growth in the number of new entrants and investments in cell and gene therapy, thereby driving a surge in demand for the consumables, equipment, and software solutions required in the manufacturing of these therapies. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the cell and gene therapy biomanufacturing market in the near future.'

Key Questions Answered in the Report

What are the key trends influencing the Asia-Pacific cell and gene therapy biomanufacturing market, and what is their potential for impacting the market?
What are the key differences in equipment offered by key players?
Who are the major end users for the cell and gene therapy biomanufacturing market? Which end user held the largest share of the market in 2021?
Who are the key players in the Asia-Pacific cell and gene therapy biomanufacturing market, and what are their product offerings in the market?

Companies Mentioned

WuXi AppTec

Table Information

Report Attribute	Details
No. of Pages	108
Published	November 2023
Forecast Period	2022 - 2031
Estimated Market Value ( USD ) in 2022	$ 1.96 Billion
Forecasted Market Value ( USD ) by 2031	$ 8.6 Billion
Compound Annual Growth Rate	17.8%
Regions Covered	Asia Pacific

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€2344EUR$2,450USD£1,951GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€3780EUR$3,950USD£3,145GBP